Alkermes plc. Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements
Alkermes plc. (ALKS) reported Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements of 9.39 million shares for the 3-month period ending 2014-06-30, per its 10-Q filed 2015-07-30.
Discontinued › Notes
us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements · last filed 2016-02-25
- Alkermes plc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2014-06-30 was 9.39M shares, a 7.07% increase year-over-year.
- Alkermes plc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2013-06-30 was 8.77M shares, a 167.61% increase year-over-year.
- Alkermes plc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2013-03-31 was 6.41M shares.
- Alkermes plc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2012-12-31 was 4.01M shares.
- Alkermes plc. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2013 was 5.39M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 3 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 6 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 6 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 9 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 12 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2014-06-30 | 9.39M shares 10-Q · filed 2015-07-30 | ||||||
| 2013-12-31 | 9.00M shares 10-K · filed 2016-02-25 | ||||||
| 2013-09-30 | 8.35M shares 10-Q · filed 2014-10-29 | ||||||
| 2013-06-30 | 8.77M shares 10-Q · filed 2014-07-31 | 7.29M shares 10-Q · filed 2013-07-25 | 7.88M shares 10-Q · filed 2014-07-31 | ||||
| 2013-03-31 | 6.41M shares 10-Q · filed 2014-04-30 | 5.39M shares 10-K · filed 2015-02-24 | 4.03M shares 10-K · filed 2013-05-23 | ||||
| 2012-12-31 | 4.01M shares 10-Q · filed 2013-01-31 | 3.73M shares 10-Q · filed 2013-01-31 | |||||
| 2012-09-30 | 4.84M shares 10-Q · filed 2013-10-31 | 3.60M shares 10-Q · filed 2012-11-01 | |||||
| 2012-06-30 | 3.28M shares 10-Q · filed 2013-07-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |